Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III Study of Ipatasertib Plus Atezolizumab and Paclitaxel in Advanced or Metastatic Triple-Negative Breast Cancer
2019-000810-12Phase 3Completed
- Sponsor
- Roche
- Start
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ipatasertib in triple-negative breast cancer (TNBC) and breast cancer (2 arms), sponsored by Roche. Primary endpoints: Investigator-assessed progression-free survival (PFS) and Overall survival (OS). Started Oct 2019; status: completed.
02
Drugs
ipatasertib
03
Conditions
triple-negative breast cancer (TNBC)breast cancer
Beyond the preview
Go deeper on 2019-000810-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000810-12.